UBS Group
TECX

UBS Group’s Tectonic Therapeutic TECX Stock Holding History

UBS Group’s Portfolio TECX Stock Details TECX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$518K Sell
15,055
-14,932
-50% -$439K ﹤0.01% 6205
2026
Q1 		$927K Sell
29,987
-1,228
-4% -$30.2K ﹤0.01% 5606
2025
Q4 		$651K Sell
31,215
-35,245
-53% -$655K ﹤0.01% 5913
2025
Q3 		$1.04M Buy
66,460
+32,222
+94% +$665K ﹤0.01% 5541
2025
Q2 		$680K Buy
34,238
+23,011
+205% +$467K ﹤0.01% 5760
2025
Q1 		$199K Buy
11,227
+453
+4% +$14.8K ﹤0.01% 6565
2024
Q4 		$497K Buy
10,774
+10,771
+359,033% +$456K ﹤0.01% 5835
2024
Q3 		$91 Buy
+3
New +$55 ﹤0.01% 9167
2023
Q4 		– Sell
-823
Closed -$15.2K – 9990
2023
Q3 		$15.2K Buy
823
+818
+16,360% +$14.5K ﹤0.01% 6936
2023
Q2 		$62 Hold
5
– – ﹤0.01% 8577
2023
Q1 		$65 Hold
5
– – ﹤0.01% 9308
2022
Q4 		$46 Sell
5
-1,864
-100% -$16.4K ﹤0.01% 10483
2022
Q3 		$14K Buy
+1,869
New +$20.7K ﹤0.01% 7936
2022
Q2 		– Sell
-206
Closed -$3K – 11054
2022
Q1 		$3K Sell
206
-210
-50% -$4.34K ﹤0.01% 9500
2021
Q4 		$19K Buy
416
+249
+149% +$14.3K ﹤0.01% 7919
2021
Q3 		$11K Sell
167
-333
-67% -$27.3K ﹤0.01% 7912
2021
Q2 		$53K Buy
500
+472
+1,686% +$56K ﹤0.01% 6384
2021
Q1 		$4K Sell
28
-126
-82% -$20.5K ﹤0.01% 8438
2020
Q4 		$26K Buy
+154
New +$27.4K ﹤0.01% 6757
2020
Q3 		– Sell
-98
Closed -$20K – 8473
2020
Q2 		$20K Sell
98
-13,825
-99% -$2.85M ﹤0.01% 6566
2020
Q1 		$2.6M Buy
13,923
+13,813
+12,557% +$3.25M ﹤0.01% 2513
2019
Q4 		$27K Sell
110
-4,372
-98% -$843K ﹤0.01% 6710
2019
Q3 		$759K Sell
4,482
-310
-6% -$70.2K ﹤0.01% 4206
2019
Q2 		$935K Buy
4,792
+1,580
+49% +$341K ﹤0.01% 3802
2019
Q1 		$850K Buy
3,212
+3,194
+17,744% +$584K ﹤0.01% 3704
2018
Q4 		$4K Sell
18
-120
-87% -$36.5K ﹤0.01% 7650
2018
Q3 		$86K Sell
138
-8
-5% -$3.55K ﹤0.01% 5714
2018
Q2 		$50K Buy
+146
New +$52.7K ﹤0.01% 5962

Other funds holding TECX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

UBS Group's TECX Position: Q2 2026 in Review

UBS Group reduced its Tectonic Therapeutic (TECX) stake by 50% in Q2 2026, selling an estimated $439K and leaving 15,055 shares worth $518K. The position accounts for ﹤0.01% of the portfolio, ranked #6205.

UBS Group first reported a position in TECX in Q2 2018 and has held it in 28 quarters since. The position peaked at $2.6M in Q1 2020. 123 funds tracked by Wall St. Rank hold TECX as of Q2 2026.

  • UBS Group held 15,055 shares of Tectonic Therapeutic worth $518K as of Q2 2026.
  • UBS Group sold 14,932 Tectonic Therapeutic shares in Q2 2026, an estimated $439K.
  • Tectonic Therapeutic made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6205 holding.
  • UBS Group first reported a position in Tectonic Therapeutic in Q2 2018 and has held it in 28 quarters since.
  • UBS Group's Tectonic Therapeutic position peaked at $2.6M in Q1 2020.
  • 123 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.